Abstract
Objective:
To assess the detection of tumour markers in the cyst fluid of residual cystic non-seminomatous germ cell tumours disease post chemotherapy at the time of retroperitoneal lymph node dissection (RPLND) and assess the correlation with pre-treatment serum markers.
Materials and Methods:
In this prospective study (May 2018–July 2023), cystic fluid was aspirated from residual masses during RPLND in 24 patients. Tumour markers alpha-fetoprotein (AFP), human chorionic gonadotropin (HCG), and lactate dehydrogenase (LDH) were measured and correlated with serum markers and histopathology.
Results:
Twenty-four out of 26 (92.3%) cystic teratoma cases showed elevated AFP, HCG, or both in cystic fluid despite normalised serum markers post chemotherapy. No significant correlation was observed between serum and cystic fluid marker levels. One benign case showed no detectable cystic markers. Cystic tumour marker levels were independent of primary testicular tumour histology.
Conclusion:
Cystic fluid tumour marker analysis at the time of post-chemotherapy RPLND frequently demonstrated elevated AFP and/or HCG in teratoma, even when serum markers were normal. There could be a role for assessment of cyst fluid tumour markers in patients with new cystic masses arising post RPLND to predict recurrence of teratoma. However, larger, multicentre studies including diverse cystic pathologies are needed to clarify the diagnostic accuracy and potential role of this approach in clinical decision-making.
Level of Evidence:
2b
Keywords
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
